Eric A. Murphy

2.5k total citations · 1 hit paper
20 papers, 1.9k citations indexed

About

Eric A. Murphy is a scholar working on Molecular Biology, Oncology and Cell Biology. According to data from OpenAlex, Eric A. Murphy has authored 20 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Molecular Biology, 5 papers in Oncology and 5 papers in Cell Biology. Recurrent topics in Eric A. Murphy's work include Angiogenesis and VEGF in Cancer (4 papers), Cell Adhesion Molecules Research (4 papers) and Melanoma and MAPK Pathways (3 papers). Eric A. Murphy is often cited by papers focused on Angiogenesis and VEGF in Cancer (4 papers), Cell Adhesion Molecules Research (4 papers) and Melanoma and MAPK Pathways (3 papers). Eric A. Murphy collaborates with scholars based in United States. Eric A. Murphy's co-authors include David A. Cheresh, David J. Shields, Sara M. Weis, Bharat K. Majeti, Lisette M. Acevedo, Lea Scheppke, Leo A. Barnes, Wolfgang Wrasidlo, Joshua I. Greenberg and Milan Makale and has published in prestigious journals such as Nature, Proceedings of the National Academy of Sciences and Nature Medicine.

In The Last Decade

Eric A. Murphy

20 papers receiving 1.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

A role for VEGF as a negative regulator of pericyte function and vessel maturation

2008 501 citations Joshua I. Greenberg, David J. Shields et al. Nature profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Eric A. Murphy United States	11	1.2k	523	344	330	267	20	1.9k
Miriam Benezra United States	20	1.2k 1.0×	356 0.7×	413 1.2×	343 1.0×	386 1.4×	28	2.3k
Sven Christian Germany	22	1.6k 1.3×	552 1.1×	587 1.7×	167 0.5×	323 1.2×	33	2.3k
Yuliang Ran China	23	689 0.6×	348 0.7×	345 1.0×	228 0.7×	225 0.8×	55	1.5k
Serena Marchiò Italy	25	990 0.8×	273 0.5×	494 1.4×	178 0.5×	245 0.9×	45	1.9k
Sylvie Roberge United States	18	1.1k 0.9×	488 0.9×	578 1.7×	481 1.5×	654 2.4×	39	2.5k
Marina V. Backer United States	25	838 0.7×	313 0.6×	211 0.6×	246 0.7×	523 2.0×	61	1.9k
Antonella Zannetti Italy	27	1.1k 0.9×	426 0.8×	669 1.9×	145 0.4×	213 0.8×	66	2.0k
Quang‐Dé Nguyen United Kingdom	25	1.0k 0.8×	355 0.7×	642 1.9×	132 0.4×	215 0.8×	53	2.1k
Guido Piontek Germany	26	684 0.6×	230 0.4×	492 1.4×	254 0.8×	363 1.4×	58	2.0k
Jacqueline Banyard United States	14	593 0.5×	266 0.5×	309 0.9×	203 0.6×	169 0.6×	18	1.1k

Countries citing papers authored by Eric A. Murphy

Since Specialization

Citations

This map shows the geographic impact of Eric A. Murphy's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eric A. Murphy with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eric A. Murphy more than expected).

Fields of papers citing papers by Eric A. Murphy

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Eric A. Murphy. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eric A. Murphy. The network helps show where Eric A. Murphy may publish in the future.

Co-authorship network of co-authors of Eric A. Murphy

This figure shows the co-authorship network connecting the top 25 collaborators of Eric A. Murphy. A scholar is included among the top collaborators of Eric A. Murphy based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Eric A. Murphy. Eric A. Murphy is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Chen, Young K., Toufike Kanouni, Lee D. Arnold, et al.. (2024). The Discovery of Exarafenib (KIN-2787): Overcoming the Challenges of Pan-RAF Kinase Inhibition. Journal of Medicinal Chemistry. 67(3). 1747–1757. 5 indexed citations

Murphy, Eric A., et al.. (2024). Abstract LB173: Discovery of ALTA-2618, the first allosteric, mutant-selective targeted therapy for AKT1 E17K driven cancers. Cancer Research. 84(7_Supplement). LB173–LB173. 1 indexed citations

Tyhonas, John, Lee D. Arnold, Jason M. Cox, et al.. (2024). Discovery of KIN-3248, An Irreversible, Next Generation FGFR Inhibitor for the Treatment of Advanced Tumors Harboring FGFR2 and/or FGFR3 Gene Alterations. Journal of Medicinal Chemistry. 67(3). 1734–1746. 10 indexed citations

Franovic, Aleksandra, Sean Uryu, Qibiao Wu, et al.. (2022). Activity of KIN-3248, a next-generation pan-FGFR inhibitor, against acquired FGFR-gatekeeper and molecular-brake drug resistance mutations.. Journal of Clinical Oncology. 40(4_suppl). 461–461. 7 indexed citations

Franovic, Aleksandra, Nichol Miller, Paul Severson, et al.. (2021). The next-generation pan-RAF inhibitor, KIN-2787, is active in class II and class III BRAF mutant models.. Journal of Clinical Oncology. 39(15_suppl). 3116–3116. 9 indexed citations

Jia, Yong, Jose Juarez, Mari Manuia, et al.. (2014). Abstract 1734: In vitro characterization of EGF816, a third-generation mutant-selective EGFR inhibitor. Cancer Research. 74(19_Supplement). 1734–1734. 4 indexed citations

Kasibhatla, Shailaja, Jie Li, Celin Tompkins, et al.. (2014). Abstract 1733: EGF816, a novel covalent inhibitor of mutant-selective epidermal growth factor receptor, overcomes T790M-mediated resistance in NSCLC. Cancer Research. 74(19_Supplement). 1733–1733. 8 indexed citations

Lau, Steven, David J. Shields, Eric A. Murphy, et al.. (2012). EGFR-Mediated Carcinoma Cell Metastasis Mediated by Integrin αvβ5 Depends on Activation of c-Src and Cleavage of MUC1. PLoS ONE. 7(5). e36753–e36753. 33 indexed citations

Murphy, Eric A., Bharat K. Majeti, Rajesh Mukthavaram, et al.. (2011). Targeted Nanogels: A Versatile Platform for Drug Delivery to Tumors. Molecular Cancer Therapeutics. 10(6). 972–982. 62 indexed citations

10.

Mielgo, Ainhoa, Laetitia Seguin, Miller Huang, et al.. (2011). A MEK-independent role for CRAF in mitosis and tumor progression. Nature Medicine. 17(12). 1641–1645. 54 indexed citations

11.

Scheppke, Lea, Eric A. Murphy, Alessandro Zarpellon, et al.. (2011). Notch promotes vascular maturation by inducing integrin-mediated smooth muscle cell adhesion to the endothelial basement membrane. Blood. 119(9). 2149–2158. 116 indexed citations

12.

Anand, Sudarshan, Bharat K. Majeti, Lisette M. Acevedo, et al.. (2010). MicroRNA-132–mediated loss of p120RasGAP activates the endothelium to facilitate pathological angiogenesis. Nature Medicine. 16(8). 909–914. 418 indexed citations

13.

Murphy, E. J., Eric A. Murphy, & Thad A. Rosenberger. (2010). Lipid-Mediated Signaling. 5 indexed citations

14.

Murphy, Eric A., David J. Shields, Konstantin Stoletov, et al.. (2010). Disruption of angiogenesis and tumor growth with an orally active drug that stabilizes the inactive state of PDGFRβ/B-RAF. Proceedings of the National Academy of Sciences. 107(9). 4299–4304. 50 indexed citations

15.

Shields, David J., Sherry Niessen, Eric A. Murphy, et al.. (2009). RBBP9: A tumor-associated serine hydrolase activity required for pancreatic neoplasia. Proceedings of the National Academy of Sciences. 107(5). 2189–2194. 52 indexed citations

16.

Koh, Wonshill, Kamakshi Sachidanandam, Amber N. Stratman, et al.. (2009). Formation of endothelial lumens requires a coordinated PKCϵ-, Src-, Pak- and Raf-kinase-dependent signaling cascade downstream of Cdc42 activation. Journal of Cell Science. 122(11). 1812–1822. 72 indexed citations

17.

Greenberg, Joshua I., David J. Shields, Lisette M. Acevedo, et al.. (2008). A role for VEGF as a negative regulator of pericyte function and vessel maturation. Nature. 456(7223). 809–813. 501 indexed citations breakdown →

18.

Murphy, Eric A., Bharat K. Majeti, Leo A. Barnes, et al.. (2008). Nanoparticle-mediated drug delivery to tumor vasculature suppresses metastasis. Proceedings of the National Academy of Sciences. 105(27). 9343–9348. 370 indexed citations

19.

Rapoport, Stanley I., et al.. (2001). ATP synthesis is coupled to rat liver mitochondrial RNA synthesis. Molecular and Cellular Biochemistry. 221(1-2). 3–10. 8 indexed citations

20.

Balaban, Naomi, et al.. (1996). The effect of ionizing radiation on signal transduction: antibodies to EGF receptor sensitize A431 cells to radiation. Biochimica et Biophysica Acta (BBA) - Molecular Cell Research. 1314(1-2). 147–156. 123 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact